RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress May 2, 2025 07:00AM
RedHill Biopharma (RDHL) Secures Allowance of Chinese Patent Application for RHB-107 Apr 28, 2025 07:05AM
RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107 Apr 28, 2025 07:03AM
Talicia® Launched in the United Arab Emirates Aug 21, 2024 07:00AM
RedHill Biopharma (RDHL) Terminates License Agreement for Aemcolo Jul 9, 2024 08:04AM
View Older Stories

Jul 9, 2024 08:00AM RedHill Biopharma Terminates License Agreement for Aemcolo®
Jun 3, 2024 07:00AM RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040
May 6, 2024 07:00AM RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
Apr 24, 2024 07:02AM RedHill Biopharma (RDHL) Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
Apr 24, 2024 07:00AM RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study
Apr 8, 2024 09:23AM RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
Apr 2, 2024 07:01AM RedHill Biopharma (RDHL) Prices 2.14M Share Offering at $0.58/sh
Apr 2, 2024 07:00AM RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price
Mar 11, 2024 07:04AM RedHill Biopharma (RDHL) Announces New USPTO Patent Covering Talicia Through 2034
Mar 11, 2024 07:00AM RedHill Announces New USPTO Patent Covering Talicia® Through 2034
Mar 5, 2024 07:03AM RedHill Biopharma's (RDHL) Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
Mar 5, 2024 07:00AM RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
Feb 20, 2024 07:00AM RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication
Jan 26, 2024 12:46PM RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering
Jan 25, 2024 09:06AM RedHill Biopharma (RDHL) Announces 10M Share Offering at $0.80/sh
Jan 25, 2024 09:05AM RedHill Biopharma Announces $8 Million Registered Direct Offering
Jan 25, 2024 06:00AM RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042
Dec 20, 2023 08:45AM RedHill (RDHL) and U.S. Army Report Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Dec 20, 2023 08:45AM RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola
Dec 12, 2023 07:00AM RedHill Biopharma (RDHL) Regains Nasdaq Compliance
Dec 12, 2023 07:00AM RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Dec 4, 2023 07:05AM RedHill Biopharma (RDHL) Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
Dec 4, 2023 07:00AM RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study
Nov 27, 2023 07:00AM RedHill Biopharma (RDHL) Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia with IP Protection Running to 2034
Nov 27, 2023 07:00AM RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034
Nov 14, 2023 08:00AM RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market
Oct 3, 2023 07:03AM RedHill Biopharma (RDHL) and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study
Oct 3, 2023 07:00AM RedHill and U.S. Army Announce Opaganib's Ebola Virus Disease Survival Benefit in U.S. Army-Funded In-Vivo Study
Sep 22, 2023 04:15PM RedHill Biopharma (RDHL) Receives NASDAQ Non-compliance Notice
Sep 22, 2023 04:15PM RedHill Biopharma Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Sep 18, 2023 07:00AM RedHill Biopharma (RDHL) Announces FDA sNDA Approval for Talicia
Sep 18, 2023 07:00AM RedHill Announces FDA sNDA Approval for Talicia®
Sep 5, 2023 07:02AM RedHill Biopharma (RDHL) announced U.S. patent allowance for new opaganib patent
Sep 5, 2023 07:00AM RedHill Announces New USPTO Notice of Patent Allowance for Opaganib and EU Patent Grant for RHB-102 (BEKINDA®)
Aug 18, 2023 07:52AM This Week in Health News: 11 Stories You Need to See
Aug 17, 2023 07:00AM RedHill Biopharma Provides H1/23 Financial Results and Operational Highlights
Aug 1, 2023 07:00AM RedHill Biopharma Announces Talicia Approved in the United Arab Emirates and First Commercial Order Outside the U.S.
Jul 31, 2023 07:01AM RedHill Biopharma's (RDHL) RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial
Jul 31, 2023 07:00AM RedHill's RHB-107 Included in U.S. Government-Supported COVID-19 Platform Trial and Cleared for Initiation by FDA
Jul 25, 2023 03:58PM RedHill Biopharma Announces Closing of $3.8 Million Registered Direct Offering and Warrant Exercise
Jul 21, 2023 09:34AM RedHill Biopharma (RDHL) Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds
Jul 21, 2023 09:33AM RedHill Biopharma Announces Registered Direct Offering and Warrant Exercise for $3.8 Million Gross Proceeds
Jul 21, 2023 07:00AM RedHill Biopharma (RDHL) Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development
Jul 21, 2023 07:00AM RedHill Announces Additional U.S. Government Funding for Opaganib Nuclear Countermeasure Development
Jul 6, 2023 08:00AM Phil and RedHill Biopharma Partner to Increase Access to Talicia®
Jun 12, 2023 08:00AM RedHill Biopharma Announces Q1/2023 Financial Results and Operational Highlights
May 22, 2023 07:01AM RedHill Biopharma (RDHL) Provides R&D Update
May 22, 2023 07:00AM RedHill Provides R&D Update
May 15, 2023 06:24PM RedHill Biopharma (RDHL) Receives NASDAQ Non-compliance Notice
May 15, 2023 06:17PM RedHill Biopharma Receives NASDAQ Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency
View Older Stories